Avidity Corp (RNA) - Business Payback Period

Symbol and logo of brand Avidity Biosciences Inc (RNA)

Avidity Biosciences leads in muscle therapy thanks to a unique RNA molecule delivery method. The business's price-to-earnings ratio cuts through market noise, demonstrating the real payback period, where the value of -16.30 reflects this status. Conjugate patents protect the company from pharma behemoths, while the clinical portfolio scaling strategy paves the way for the imminent commercial launch of drugs.

RNA: Avidity Price to Earnings Ratio 07/04/2022 - 02/27/2026

Comprehensive metric breakdowns and analytics for Avidity (RNA)

- current price and projected stock value:
Share Price aviditybiosciences.com|RNA - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Avidity Biosciences, Inc.|RNA - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Avidity Biosciences|RNA - Company Net Assets|Market-to-Book Ratio aviditybiosciences.com|RNA - Cumulative Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Avidity Biosciences|RNA - Long-Term Debt to Capital|Short-Term Debt to Equity Avidity Corp|RNA - Company Aggregate Debts|Debts to Net Assets Avidity Biosciences, Inc.|RNA - Company Long-Term Debt|Short-Term Debt Avidity Biosciences|Interim Coverage Ratio aviditybiosciences.com
- earnings and valuation multiples information:
RNA - Net Profit|Future Profit Avidity Biosciences|RNA - P/E Multiple|Market Cap to Projected Earnings Avidity Biosciences Inc|RNA - PEG Multiple|Company Value to EBITDA Avidity Biosciences, Inc.|RNA - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Avidity Biosciences|RNA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months aviditybiosciences.com|RNA - Earnings growth in current year|Expected net earnings per share growth next year Avidity Biosciences
Summary company analysis:Avidity Biosciences
Flagship merchandise of Avidity Corp

Avidity Biosciences (RNA) specializes in the development of RNA therapies and is currently in the clinical trial stage with no current revenue or profit. An analysis of the company's median P/E allows for an assessment of market expectations regarding future earnings, while abnormal fluctuations in this indicator serve as a stress test of the issuer's financial stability, signaling risks of capital freeze to investors in the absence of operational cash flow.

Analysis of competing companies

Price to Earnings Multiple TEM (Tempus AI Inc)|P/E Multiple QGEN|Business Payback Period Ionis Pharmaceuticals, Inc.|Repligen Corp. - Price to Earnings Ratio|Market Price to Net Income Ratio CRSP (CRISPR)|WGS: Price to Earnings Ratio|Market Cap to Earnings ultragenyx.com|BEAM (Beam Therapeutics) - Price to Earnings Ratio|Sarepta Therapeutics - Company Value to Net Income|TWST (Twist Bio) - P/E Multiple|Price to Earnings Ratio TXG|P/E Multiple NTLA|Business Payback Period stoketherapeutics.com|Price to Earnings Ratio BioLife Solutions BLFS|Wave Life Sciences Ltd (WVE) - Market Cap to Earnings|MAZE - Price to Earnings Ratio|Business Payback Period Sionna Corp SION|PRME: P/E Multiple|Price to Earnings Ratio tayshagtx.com|QURE (uniQure) - P/E Multiple|MeiraGTx Holdings (MGTX) - Business Payback Period|P/E Multiple RGNX|SLDB - Market Cap to Earnings|Price to Earnings Ratio Ocugen, Inc. OCGN|PACB: Price to Earnings Multiple|Benitec Biopharma - P/E Multiple|Design Therapeutics Inc (DSGN) - Price to Earnings Ratio|RCKT: P/E Multiple|Market Cap to Earnings 4D Molecular Corp (FDMT)|Price to Earnings Ratio Lexeo Therapeutics Inc.|Korro Bio, Inc (KRRO) - Business Payback Period|Price to Earnings Ratio Editas Medicine (EDIT)|SLN (Silence Therapeutics PLC) - Company Value to Net Income|Price to Earnings Ratio ProQR Therapeutics PRQR|CDXS: Price to Earnings Multiple|Sangamo Therapeutics - P/E Multiple|NAUT - P/E Multiple|MGX: P/E Multiple|Price to Earnings Multiple DTIL|Price to Earnings Ratio Generation Bio Co|Price to Earnings Multiple BOLD (Boundless Bio Inc)|P/E Multiple XCUR|P/E Multiple imunon.com (IMNN)|P/E Multiple PHIO (Phio Pharmaceuticals Corp.)|P/E Multiple Mustang Bio Inc MBIO|RNAZ: Price to Earnings Ratio|BNGO: Price to Earnings Ratio|APDN: P/E Multiple|BLUE - Business Payback Period|IPA (ImmunoPrecise Antibodies Ltd) - P/E Multiple|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|P/E Multiple OMIC|Business Payback Period Regulus|Syros Pharmaceuticals - Price to Earnings Ratio|Market Price to Net Income Ratio TBIO (telesisbio.com)|TCON: Price to Earnings Ratio|Market Cap to Earnings Unity Biotechnology Inc.